4.4 Article

Factors associated with the transition from abuse to dependence among substance abusers: Implications for a measure of addictive liability

Journal

DRUG AND ALCOHOL DEPENDENCE
Volume 80, Issue 1, Pages 1-14

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.drugalcdep.2005.02.005

Keywords

abuse; dependence; abuse liability; etiology

Funding

  1. Intramural NIH HHS [Z01 DA000434] Funding Source: Medline
  2. NIAAA NIH HHS [AA12111, R01 AA012111] Funding Source: Medline
  3. NIDA NIH HHS [R01 DA015984, K01 DA000434, DA15984, DA00430, K01 DA000430] Funding Source: Medline
  4. NIMH NIH HHS [T32 MH017104, MH17104] Funding Source: Medline

Ask authors/readers for more resources

This study was conducted to test the validity of a measure that has potential to bridge research on the addictive liability of drugs and on individuals' liability to addiction, which to date have evolved in largely parallel arenas. The length of time between onset of abuse and dependence (LOTAD) has evolved from recent findings on transitions through levels of addiction; it was hypothesized that shorter LOTAD is indicative of greater addictive liability. Hypotheses were based on animal studies and human studies. Retrospective data from the DSM-IV Substance Use Disorders Work Group were reanalyzed using configural frequency analysis, survival curves, bivariate Kendall's tau associations, and linear regression. The sample consisted of participants recruited from community and clinical settings. The measure was the Composite International Diagnostic Interview-Substance Abuse Module (CIDI-SAM). The shortest LOTADs were observed for disorders related to use of cocaine and opiates, followed by cannabis and then alcohol regardless of the subsample that was analyzed. As hypothesized, females and early initiators of drug use had shorter LOTADs compared to men and other initiators of drug use; no consistent differences in LOTAD were observed between African-Americans and Caucasians. None of the LOTAD variance associated with differences between drugs could be accounted for by gender, early use of the drug, or ethnicity. Specific areas of research where LOTAD might be useful as well as how LOTAD might be improved are discussed. (c) 2005 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available